EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe

Enver Aydilek iD, Gerald Wulf, Friedrich Schwarz iD, Ulrike Bacher iD, Mathias Rummel, Olga Stiefel, Andrea Kerkhoff, Markus Maulhardt, Thomas Melchardt, Thomas Pabst, Georg Lenz, Evgenii Shumilov

Cancer Medicine · 2024

DOI: 10.1002/cam4.7289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Enver Aydilek und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Compassionate Use Trials. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mantle cell lymphoma (MCL) is a type of B‐cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real‐world data are scarce.

Methods

In this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP).

Results

On average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow‐up of 8.6 months, the mean duration of response (DOR), progression‐free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented.

Conclusions

In summary, pirtobrutinib represented a safe and effective treatment option in a small real‐world population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellCompassionate Use TrialsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesEuropeTreatment OutcomeNeoplasm Recurrence, LocalAged, 80 and overProtein Kinase InhibitorsProgression-Free SurvivalAdultDrug Resistance, Neoplasm

Stichwörter der Autor:innen

compassionate use programmantle cell lymphomaoutcomespirtobrutinib

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Campus Institute for Dynamics of Biological Networks, Georg August University, Göttingen, Germany.
  • Department of Hematology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
  • Department of Hematology, Clinic for Haematology and Medical Oncology, Justus Liebig University Hospital, Gießen, Germany.
  • Division of Hematology With Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Linz, Austria.
  • Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.

ORCID-Profile: Enver Aydilek, Friedrich Schwarz, Ulrike Bacher

Zitieren

APA

Aydilek, E., Wulf, G., Schwarz, F., Bacher, U., Rummel, M., Stiefel, O., Kerkhoff, A., Maulhardt, M., Melchardt, T., Pabst, T., Lenz, G., & Shumilov, E. (2024). Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe. Cancer Medicine. https://doi.org/10.1002/cam4.7289

Vancouver

Aydilek E, Wulf G, Schwarz F, Bacher U, Rummel M, Stiefel O, et al. Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe. Cancer Medicine. 2024. doi:10.1002/cam4.7289

BibTeX
@article{Aydilek2024,
  author = {Aydilek, Enver and Wulf, Gerald and Schwarz, Friedrich and Bacher, Ulrike and Rummel, Mathias and Stiefel, Olga and Kerkhoff, Andrea and Maulhardt, Markus and Melchardt, Thomas and Pabst, Thomas and Lenz, Georg and Shumilov, Evgenii},
  title = {Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7289}
}
Kostenlos starten →